Compare AbbVie Inc (ABBV) vs Snowflake Inc (SNOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Snowflake Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Snowflake Inc trades at $260.1 (market cap $91.07B). The key difference: AbbVie Inc is far larger — about 4.9× Snowflake Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| ABBV | SNOW | |
|---|---|---|
Market Cap | $449.91B | $91.07B |
Sector | Health | Technology |
52-Week High | $261.07 | $280.16 |
52-Week Low | $184.85 | $121.11 |
Enterprise Value | $513.38B | $90.88B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
SNOW trades at $262.74, up 1.0% today, with a bullish technical outlook from moving averages and strong analyst consensus. The stock shows accelerating revenue growth, reaching $3.63B in 2025, but remains unprofitable with a net income margin of -23.79%. Recent news highlights AI Data Cloud traction and partnerships driving optimism, while cash flow from operations improved to $959.76M.
Outlook is positive due to AI-driven growth and consistent earnings beats, but high valuation (P/S 17.74) and persistent losses pose risks. Wall Street's $294.31 price target suggests ~12% upside, though competition and execution challenges require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
